Skip to main content

SG STOCKS PICK

Search This Blog

Zero Certs vs Warrants | Zero certs vs ETF and Unit Trusts

February 03, 2008

Get link
Facebook
X
Pinterest
Email
Other Apps

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Popular Posts

Singapore Kitchen Equipment Ltd: Brewing a nice dish for shareholders !

Singapore Kitchen(SKE) was listed on SGX in 2013 at a price of 20cts. It has hit a high of 25cts on 19th June 2014, a low of 7.3cts in early 2016. Investment Merits: 1) Company has only $0.4 million of long term debt vs a net cash position. 2) 2 main segment of business: 1) Distribution & Fabrication of kitchen equipment 2) Maintenance & Servicing: Abt 75% of revenue is accounted for Distribution & Fabrication of kitchen equipment, with 25% of revenue as recurring income. As years go by, i am sure the recurring revenue will keep increasing. 3) With robotic machinery, the product can automated and increase efficiency in kitchens. This may be a stepping stone for SKE to widen its client base. 4) Profit has grown from $0.11 million upon listing to $2.57 million in FY2016. Its ROA and ROE is 11.75% and 17% respectively. In the last 4 years of listing, SKE has slowly growing. 5) Decent dividend yield of 4.69% base on last traded price of 16cts. 6) Single digit PE o...

STAR PHARMACEUTICAL LIMITED: A Star in SGX ?

STAR Pharmaceutical Limited is an investment holding company. The principal activities of the subsidiaries are those relating to the development, manufacturing and trading of pharmaceutical products. The Company operates in the development, manufacturing and trading of pharmaceutical products segment. The Company and its subsidiaries are engaged in the manufacture and sale of both western and Traditional Chinese Medicine (TCM)-formulated prescription drugs. The Company's range of pharmaceutical products include antibiotics, cerebrovascular drugs and cardiovascular drugs, and other specialized drugs manufactured in-house in various dosages and administration forms from powder injections, lyophilized powder injections, liquid injections to tablets, capsules and granules. It has approximately 820 distributors to hospitals, clinics and pharmacies. The Company has a manufacturing facility based in Qionghai City, Hainan Province of People's Republic of China. ( Taken from Thomso...

PRIME US REIT: Is this an opportunity?

At this point of writing, PRIME is trading at US$0.30. Its yield is now almost 20%, at US$0.06 ( base on FY2022). Trading a 0.44x book value, NTA is US$0.75. Let take a look at a few metrices. 1) Weighted Average Lease Expiry (WALE) is 4.1 years, which provides sufficient time to cushion any volatility in the stock market. 2) Weighted Average Debt Maturity is 2 years. This may raise some concerns here. Out of the US$449 million debt maturity in 2024, US$160 million can be extended to July 2026 ( 2 years extension ), bringing Weighted Average Debt Maturity to 2.7 years. Personally, I am not sure if this provide sufficient buffer time for PRIME to obtain new loan facilities. 3) Average leverage is 42%. This figure is still below the requirements of 50%. Summary: All investments come with RISK, some is higher while some is lower. At a yield of close to 20%, and trading at 0.44x book value, i think the risk is justified.

Powered by Blogger